Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 28, 2023

Semaglutide in Patients With HFpEF Across Obesity Class and by Body Weight Reduction

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Nat. Med. 2023 Sep 01;29(9)2358-2365, BA Borlaug, DW Kitzman, MJ Davies, S Rasmussen, E Barros, J Butler, MN Einfeldt, GK Hovingh, DV Møller, MC Petrie, SJ Shah, S Verma, W Abhayaratna, FZ Ahmed, V Chopra, J Ezekowitz, M Fu, H Ito, M Lelonek, V Melenovsky, J Núñez, E Perna, M Schou, M Senni, P van der Meer, D Von Lewinski, D Wolf, MN Kosiborod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading